Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03527056
Other study ID # 16-001946
Secondary ID
Status Withdrawn
Phase Early Phase 1
First received
Last updated
Start date June 2019
Est. completion date September 24, 2019

Study information

Verified date October 2019
Source University of California, Los Angeles
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Carbapenem-Resistant Enterobacteriaceae (CRE) are bacteria that have become resistant to carbapenems by producing enzymes that break down carbapenems. The prevalence of CRE continues to rise globally but the treatment options are extremely limited. In case series, isolation of CRE from any site, whether there is clinical infection or not, has been associated with all-cause hospital mortality ranging from 29% to 52%. There are no known methods for reliably decolonizing gastrointestinal (GI) CRE. In rare case reports, fecal microbiota transplant (FMT) has successfully eradicated gastrointestinal colonization of CRE, but there has been no larger study further investigating this. FMT via oral capsules is the least invasive method and has demonstrated efficacy and short-term safety in treating patients with recurrent Clostridium difficile infections. Therefore, the investigators propose this pilot study to determine the effectiveness of oral capsule fecal transplantation in the decolonization of gastrointestinal CRE.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 24, 2019
Est. primary completion date September 24, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Outpatient

- Have intestinal carriage of CRE

Exclusion Criteria:

- Pregnant

- Peripheral WBC >12 x 10^9/L and/or temperature >38 degrees Celsius

- Swallowing dysfunction or known chronic aspiration

- Delayed gastric emptying

- History of intestinal obstruction

- Active CRE infection

- Acute exacerbation of underlying comorbid condition

- Severely immunocompromised patients

- Inflammatory bowel disease

- Allergies to ingredients Generally Recognized as Safe

- Adverse event attributable to previous FMT

- Concomitant antibiotic use or antibiotic use 48 hours before FMT

Study Design


Intervention

Biological:
Fecal Microbiota Transplantation
This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
University of California, Los Angeles Finch Research and Development LLC., OpenBiome

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of participants with CRE decolonization at day 10 (+/- 3 days) after fecal transplant CRE decolonization is defined by absence of CRE on stool culture using standard clinical laboratory techniques. Stool samples will be collected 10 days after FMT. 10 days
Primary Proportion of participants with an adverse event through day 10 (+/- 3 days) after FMT Telephone calls are made to participants 10 days after FMT to assess for adverse event, severe adverse event, and adverse events of special interest (newly acquired transmissible infectious diseases). 10 days
Secondary Proportion of participants with CRE decolonization at month 1 (+/-5 days) after FMT CRE decolonization is defined by absence of CRE on stool culture using standard clinical laboratory techniques. Stool samples will be collected 30 days after FMT. 1 month
Secondary Proportion of participants with CRE infection at day 10 (+/-3 days) and month 1 (+/-5 days) after FMT CRE infection will be defined as an associated bacteremia, urinary tract infection, wound-related infection or other clinical infection deemed to be CRE associated at the discretion of the treating physician. 1 month
Secondary Proportion of participants with an adverse event, severe adverse event, or adverse events of special interest through month 1 (+/-5 days) after FMT. Telephone calls are made to participants 1 month after FMT to assess for adverse event, severe adverse event, and adverse events of special interest (newly acquired transmissible infectious diseases). 1 month
Secondary Proportion of participants with a severe adverse event at month 6 (+/-14 days) after FMT. Telephone calls are made to participants 6 months after FMT to assess for severe adverse event. 6 months
Secondary Proportion of participants with microbial engraftment assessed by microbiome disruption index (MDI) (MDI-community and MDI-species) measured by 16s ribosomal RNA at time of enrollment, day 10 (+/-3 days) and month 1 (+/-5 days) after FMT Stool samples collected at baseline before FMT, day 10 after FMT, 1 month after FMT will be sent for 16s sequencing. 1 month
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04436874 - Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT05121285 - Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient N/A
Active, not recruiting NCT05917379 - The Safety and Efficacy of FMT in Patients With CID Phase 1/Phase 2
Recruiting NCT02318147 - Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC) Phase 1
Completed NCT02318134 - Fecal Microbiota Transplantation for Pancreatitis Phase 2
Completed NCT05035784 - RCE With FMT in the Treatment of Childhood Constipation N/A
Active, not recruiting NCT04173208 - Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study N/A
Terminated NCT04577729 - The IRMI-FMT Trial N/A
Not yet recruiting NCT02435160 - The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT04837313 - Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation N/A
Recruiting NCT04861649 - Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition N/A
Withdrawn NCT04078581 - Profiling Fecal Samples for Selection of Donors of Feces N/A
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT05273255 - Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy N/A
Not yet recruiting NCT05253222 - Methodology and Clinical Value of RIT in Intestinal Obstructive Diseases Mediated by Colonic TET N/A
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Recruiting NCT03018613 - Fecal Microbiota Transplantation for Chronic Functional Constipation Phase 1/Phase 2